|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent CRTX insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why CRTX insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-12-2021 Insider Buy |
Stephen S. Dominy Chief Scientific Officer |
$14.40
CAGR »
|
$10,987.20 763 shares |
3-24-2021 Insider Buy |
David Lamond Director |
$33.77
CAGR »
|
$1,688,500.00 50,000 shares |
3-4-2021 Insider Buy |
David Lamond Director |
$35.34
CAGR »
|
$1,767,057.34 50,000 shares |
6-12-2020 Insider Buy |
EPIQ Capital Group, LLC
|
$44.25
CAGR »
|
$400,018.40 9,040 shares |
6-4-2020 Insider Buy |
David Lamond Director |
$43.27
CAGR »
|
$2,125,794.96 49,125 shares |
5-22-2020 Insider Buy |
EPIQ Capital Group, LLC
|
$57.33
CAGR »
|
$498,172.24 8,690 shares |
5-19-2020 Insider Buy |
David Lamond Director |
$55.35
CAGR »
|
$2,471,251.33 44,648 shares |
5-13-2019 Insider Buy |
Kevin Young Director |
$17.00
CAGR »
|
$510,000.00 30,000 shares |
5-13-2019 Insider Buy |
Margaret McLoughlin Director |
$17.00
CAGR »
|
$9,350.00 550 shares |
5-13-2019 Insider Buy |
Una S. Ryan Director |
$17.00
CAGR »
|
$48,875.00 2,875 shares |
5-10-2019 Insider Buy |
EPIQ Capital Group, LLC
|
$26.98
CAGR »
|
$232,056.10 8,600 shares |
8-19-2019 Insider Buy |
EPIQ Capital Group, LLC
|
$26.46
CAGR »
|
$74,099.90 2,800 shares |
5-10-2019 Insider Buy |
EPIQ Capital Group, LLC
|
$26.98
CAGR »
|
$232,056.10 8,600 shares |
2-3-2014 Insider Buy |
Farmaceutici Spa Chiesi >10% Owner |
$9.50
CAGR »
|
$109,651,973.50 11,542,313 shares |
5-13-2019 Insider Buy |
Inc Pfizer >10% Owner |
$17.00
CAGR »
|
$850,000.00 50,000 shares |
2-3-2014 Insider Buy |
Farmaceutici Spa Chiesi >10% Owner |
$9.50
CAGR »
|
$109,651,973.50 11,542,313 shares |
4-3-2012 Insider Buy |
Farmaceutici Spa Chiesi >10% Owner |
$6.25
CAGR »
|
$9,024,456.25 1,443,913 shares |
3-15-2012 Insider Buy |
Farmaceutici Spa Chiesi >10% Owner |
$6.04
CAGR »
|
$41,038.00 6,800 shares |
Also See: Institutional Holders of CRTX
Also See: SEC filings
Below we present the annualized performance delivered by CRTX stock since 11-12-2021 (the date of the most recent
insider purchase). The performance of the investment from the time CRTX insider buying occurred is the ultimate
test of whether insiders were right about CRTX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/15/2021 |
|
End date: |
07/29/2022 |
|
Start price/share: |
$14.75 |
|
End price/share: |
$1.95 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-86.78% |
|
Annualized Gain: |
-124.21% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,322.00 |
|
Years: |
0.70 |
|
CRTX Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent CRTX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding CRTX
|
|